January 2016 to start new era for pharma companies in Europe

by Fleming. Team

The past decade has witnessed a wave of global transparency in the pharmaceutical industry, and 2015 has marked the start of a new era in Europe. From January 2016, pharma companies will make their transfers of value public to healthcare professionals and healthcare organisations in Europe.

Therefore, Fleming Europe has decided to gather the experts at its 4th edition of Corporate Compliance and Transparency in the Pharmaceutical Industry and make sure that these companies have entered the new year prepared.

Europe Pharma

4th Annual Corporate Compliance & Transparency in the Pharmaceutical Industry

Visit event website

On the 24th of February 2016, legal and compliance professionals from Johnson & Johnson, Novo Nordisk, Sandoz, Mylan, Actavis, Boehringer-Ingelheim, GlaxoSmithKline and many more will meet in Zurich to prepare for not only a huge technical challenge but also a major cultural shift.

During the two focused days, attendees will get an update on the Disclosure Code implementation and its first outcomes and learn how to optimise interactions with HCPs and HCOs through a fully compliant and transparent strategy.

Richard Bergstrom, Director General at EFPIA, will open the first conference day with an on-stage interview. Representatives from Novo Nordisk will present their local perspective and lessons learned. The Director General of the European Generic and Biosimilar Medicines Association will outline the Code of Conduct for the European Generic and Biosimilar Medicines Industry.

The second conference day will focus on risk assessment, communication with third parties along with their training and monitoring, internal investigations and the best practices in compliance programme structure and their effectiveness.

If you don't want your ideas to sit and gather dust, join Fleming Europe's 4th edition of Corporate Compliance and Transparency in the Pharmaceutical Industry. You are also welcome to join the discussions in the Pharma SFE & Marketing Forum

Interested in this topic?

More articles